Navigation Links
Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
Date:6/13/2013

CAMBRIDGE, Mass., June 13, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled in a Phase 1/2 clinical trial of EPZ-6438 (E7438). The trial is designed to assess the safety, tolerability and pharmacokinetics of EPZ-6438 (E7438), an orally available, small molecule inhibitor for non-Hodgkin lymphoma patients who have a cancer-causing (oncogenic) point mutation in EZH2.

Epizyme is developing EPZ-6438 (E7438) in partnership with Eisai Co., Ltd. In April 2011, the two companies announced a worldwide partnership to discover, develop and commercialize therapeutics targeting EZH2, with Epizyme retaining an opt-in right to co-develop, co-commercialize and share profits with Eisai on licensed products in the United States. As a result of the first patient enrollment in this trial, Epizyme earned a $6 million milestone payment from Eisai.

About EZH2 Cancers

EZH2 is a histone methyltransferase (HMT) that can become oncogenic and cause non-Hodgkin lymphoma and solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are mainly associated with oncogenic EZH2 mutations. Currently, there are no therapies approved specifically for the treatment of non-Hodgkin lymphoma associated with an EZH2 point mutation.

About Epizyme, Inc.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of en
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Epizyme, Inc. Announces Pricing of Initial Public Offering
2. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Epizyme to Partner to Develop DOT1L Companion Diagnostic
4. Epizyme to Present at Upcoming Conferences in February
5. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
6. Barts Hospital, London enrolls first patients in ROX Medicals CONTROL-HTN resistant hypertension trial
7. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
8. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
9. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
10. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
11. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)... Sept. 18, 2014  LABSCO, the leading ... and products to hospitals, physician office laboratories ... amended distributorship agreement with Sysmex America.  This ... instruments, including the Sysmex XS-1000 i ™, ... and XN-Series Automated Hematology Analyzers. ...
(Date:9/18/2014)... -- According to the new research ... Warming & Cooling), Application (Acute & Perioperative Care, ... & Paramedical Staff) - Global Forecasts & Trends ... global Temperature Management Market over the forecast period ... to reach $2.5 Billion by 2019 at CAGR ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4
... EyeScience(TM) ( www.eyescience.com ) announced today that ... and Dry Eye Formula(TM) are the only ... from their offices and through mass market retail. This announcement ... growing demand for the most complete eye vitamins available for ...
... (Nasdaq: HOLX ) today announced that Jack Cumming, Chairman, ... London on Tuesday, December 1, 2009, at 11:15am (GMT). ... audio webcast of Hologic,s investor presentation on the investor section ... An archive of the presentation will be available for replay ...
Cached Medicine Technology:EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 2EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 3
(Date:9/19/2014)... Business Insider Australia Rates Appy Pie as a ... Appy Pie was also listed as one of the ... Yahoo . , Appy Pie a leading cloud based DIY ... minutes and it requires no coding knowledge or previous experience ... mobile operating systems, the apps created using their platform are ...
(Date:9/19/2014)... CA (PRWEB) September 19, 2014 The ... a special promotion for new patients. Throughout the month of ... dental exam with dental X-rays for just $69. A complimentary ... patients to get their teeth and gums checked and meet ... are among the best ways to protect oral health. According ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. 18, ... got a flu shot last year, so U.S. health officials ... vaccinated for the coming flu season. "It,s really unfortunate ... flu they could get," said Dr. Thomas Frieden, director of ... morning news conference. The result is lost days from ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
(Date:9/19/2014)... LENEXA, Kan. (PRWEB) September 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for St. John’s Episcopal Hospital in Far Rockaway, N.Y. ... B. E. Smith has recently placed more than 900 ... Hospital is a faith-based, full service community hospital serving ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2Health News:Almost Everyone Needs a Flu Shot: CDC 2Health News:Almost Everyone Needs a Flu Shot: CDC 3Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 3
... to the brain can be devastating. When brain cells die, ... glutamate floods the surrounding areas, overloading the cells in its ... swathes of tissue. ,Glutamate is always present ... gaps between cells. But when this chemical is released by ...
... infections in parts of Cambodia is being extended to an ... 40,000 residents, an expert said. ,Although malaria-infected mosquitoes ... the real source of the disease is people, some of ... time without showing clear symptoms. ,Moheli island, the ...
... responsible for staphylococcus infections can kill infected patients in ... by the name of PVL or otherwise called Panton ... and harm the healthy tissue as well. ... infections. This is normally found in the skin or ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... Center researchers have identified an approach to enhance the ... shown impressive efficacy in the treatment of chronic myelogenous ... a cancer of the bone marrow caused by a ... common forms of leukemia. Imatinib mesylate (Gleevec) is a ...
... is probing the link between breast density and its implication ... novel study on 1,112 women has brought to the fore, ... with dense breasts. The study revealed that, those with dense ... breast cancer, compared to women with fatty tissue in the ...
Cached Medicine News:Health News:New Method May Treat Brain Injuries 2Health News:Chinese Scientists Take Malaria Fight to Africa 2Health News:New Strategy for the Treatment of CML 2Health News:New Strategy for the Treatment of CML 3
Duckbill type, sharp. 3 mm x 8 mm curved blade. Octagonal handle....
10 mm wide tip....
9 mm wide tip. 35 mm from angle to tip....
Designated most popular model or size. 4 mm wide tip....
Medicine Products: